Literature DB >> 27957601

Reply to a letter to the editor: Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial.

Nicole Eter1, Andreas Mohr2, Joachim Wachtlin3, Nicolas Feltgen4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27957601     DOI： 10.1007/s00417-016-3560-2

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  9 in total

1.  Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion.

Authors:  Gabriel Coscas; Albert Augustin; Francesco Bandello; Marc D de Smet; Paolo Lanzetta; Giovanni Staurenghi; Maria Cristina Parravano; Patricia Udaondo; Elad Moisseiev; Gisele Soubrane; Yossi Yatziv; Anat Loewenstein
Journal:  Eur J Ophthalmol       Date:  2013-10-14       Impact factor: 2.597

2.  Dexamethasone intravitreal implant in retinal vein occlusion:real-life data from a prospective, multicenter clinical trial.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-11-30       Impact factor: 3.117

3.  Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant.

Authors:  Wei-Shi Yeh; Julia A Haller; Paolo Lanzetta; Baruch D Kuppermann; Tien Yin Wong; Paul Mitchell; Scott M Whitcup; Jonathan W Kowalski
Journal:  Ophthalmology       Date:  2012-02-22       Impact factor: 12.079

4.  Retrospective, observational study in patients receiving a dexamethasone intravitreal implant 0.7 mg for macular oedema secondary to retinal vein occlusion.

Authors:  Albert J Augustin; Frank G Holz; Christos Haritoglou; Wolfgang J Mayer; Silvia Bopp; Alexander F Scheuerle; Matthias Maier; Walter Sekundo; Dirk Sandner; Andrew Shirlaw; Lars-Olof Hattenbach
Journal:  Ophthalmologica       Date:  2014-12-05       Impact factor: 3.250

5.  Repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion.

Authors:  Lea Querques; Giuseppe Querques; Rosangela Lattanzio; Silvia Rita Gigante; Claudia Del Turco; Giulia Corradetti; Maria Lucia Cascavilla; Francesco Bandello
Journal:  Ophthalmologica       Date:  2012-09-19       Impact factor: 3.250

6.  Inflammation in retinal vein occlusion.

Authors:  Avnish Deobhakta; Louis K Chang
Journal:  Int J Inflam       Date:  2013-04-03

7.  Two or more dexamethasone intravitreal implants as monotherapy or in combination therapy for macular edema in retinal vein occlusion: subgroup analysis of a retrospective chart review study.

Authors:  Michael A Singer; Antonio Capone; Pravin U Dugel; Richard F Dreyer; David G Dodwell; Daniel B Roth; Rui Shi; John G Walt; Lanita C Scott; David A Hollander
Journal:  BMC Ophthalmol       Date:  2015-04-01       Impact factor: 2.209

8.  Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France.

Authors:  Jean-François Korobelnik; Laurent Kodjikian; Cécile Delcourt; Vincent Gualino; Richard Leaback; Sybil Pinchinat; Marie-Eve Velard
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-11       Impact factor: 3.117

9.  Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial.

Authors:  Nicole Eter; Andreas Mohr; Joachim Wachtlin; Nicolas Feltgen; Andrew Shirlaw; Richard Leaback
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-07-26       Impact factor: 3.117
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.